Form D · Biotechnology
Renovare Therapeutics, Inc.
Boulder, CO · CIK 0002158361
Offering snapshot reported Oct 2, 2026 · SEC filing
- Reported sold
- $100K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 14, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2026 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-599827
Source: Form D, filed Oct 2, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephanie Bryant | Director |
| Karin Payne | Executive |
| Elizabeth A Scott | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8871 Tahoe Court
Boulder, CO, 80301
Phone: 919-381-7314
Boulder, CO, 80301
Phone: 919-381-7314